10x Genomics (MEX:TXG) Total Inventories : MXN1,733 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is 10x Genomics Total Inventories?

10x Genomics's total inventories for the quarter that ended in Dec. 2024 was MXN1,733 Mil. 10x Genomics's average total inventories from the quarter that ended in Sep. 2024 to the quarter that ended in Dec. 2024 was MXN1,793 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. 10x Genomics's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was MXN49.86.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. 10x Genomics's Days Inventory for the three months ended in Dec. 2024 was 145.06.

Inventory Turnover measures how fast the company turns over its inventory within a year. 10x Genomics's Inventory Turnover for the quarter that ended in Dec. 2024 was 0.63.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. 10x Genomics's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 0.52.

10x Genomics Total Inventories Historical Data

The historical data trend for 10x Genomics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

10x Genomics Total Inventories Chart

10x Genomics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Inventories

Get a 7-Day Free Trial

595.94

1,230.14

1,591.44

1,251.10

1,733.26

10x Genomics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Inventories	Get a 7-Day Free Trial															1,251.10	1,380.63	1,617.15	1,851.87	1,733.26

10x Genomics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

10x Genomics (MEX:TXG) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

10x Genomics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is

	Net-Net Working Capital Per Share (Q: Dec. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(8204.674	+	0.75 * 1832.424	+	0.5 * 1733.255	-	4348.455
-	0	-	0)	/	122.292
=	49.86

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

10x Genomics's Days Inventory for the three months ended in Dec. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2024 )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
	=	1792.564	/	1127.584	*	365 / 4
	=	145.06

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

10x Genomics's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2024 )	/	Average Total Inventories (Q: Dec. 2024 )
	=	1127.584	/	1792.564
	=	0.63

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

10x Genomics's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	1792.564	/	3441.628
	=	0.52

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

10x Genomics Total Inventories Related Terms

Thank you for viewing the detailed overview of 10x Genomics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

10x Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » 10x Genomics Inc (MEX:TXG) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

TXG:USA 0A88:UK 1KJ:Germany

Address

6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588

Website

https://www.10xgenomics.com

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).